EFFICACY AND SAFETY OF ALENDRONIC ACID IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
Abstract
Search for and practical application of new medications to treat of osteoporosis is one of the critical issues in pediatric rheumatology. The article reviews the efficacy and safety of alendronic acid in 64 subjects with juvenile rheumatoid arthritis and systemic osteoporosis. It is demonstrated that alendronate-based therapy in weekly 1 mg/kg doses over 12 months facilitated reliably increased bonedensity, decreased intensity of pain syndrome, and lowered C-terminal telopeptide serum concentration, which indicates improved bone metabolism processes.
Key words: juvenile rheumatoid arthritis, osteoporosis, children, treatment, bisphosphonates, alendronic acid.
(Pediatric Pharmacology. – 2010; 7(1):48-54)
About the Authors
A.O. LisitsinRussian Federation
E.I. Alexeeva
Russian Federation
V.G. Pinelis
Russian Federation
M.I. Bakanov
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
K.B. Isaeva
Russian Federation
G.V. Kuznetsova
Russian Federation
E.N. Arsen'eva
Russian Federation
R.V. Denisova
Russian Federation
Review
For citations:
Lisitsin A., Alexeeva E., Pinelis V., Bakanov M., Valieva S., Bzarova T., Isaeva K., Kuznetsova G., Arsen'eva E., Denisova R. EFFICACY AND SAFETY OF ALENDRONIC ACID IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS AND OSTEOPOROSIS. Pediatric pharmacology. 2010;7(1):48-54.
Email this article 